A Director at Jazz Pharmaceuticals (NASDAQ: JAZZ) is Buying SharesBy Carrie Williams
This recent transaction increases Kenneth O’keefe’s holding in the company by 17.69% to a total of $1.21 million. In addition to Kenneth O’keefe, one other JAZZ executive reported Buy trades in the last month.
Based on Jazz Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $374 million and quarterly net profit of $87.15 million. In comparison, last year the company earned revenue of $341 million and had a net profit of $87.96 million. The company has a one year high of $160 and a one year low of $95.80. JAZZ’s market cap is $6.77B and the company has a P/E ratio of 19.73.
21 different firms, including Leerink Swann and Aegis Capital, currently also have a Buy rating on the stock. Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $173.43, reflecting a -35.2% downside. Starting in September 2016, JAZZ received 13 Buy ratings in a row.
The insider sentiment on Jazz Pharmaceuticals has been neutral according to 86 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. It has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd on January 18, 2012 and is headquartered in Dublin, Ireland.